Unnatural Products to be Acquired by argenx for Up to $1.15 Billion
argenx has announced its acquisition of Unnatural Products for up to $1.15 billion to enhance its portfolio of next-generation medicines. This acquisition highlights the growing trend of consolidation in the biotech sector, which could impact investment strategies and market dynamics. InfraSale's audience should monitor how this deal influences R&D capabilities and future collaborations in healthcare.
Read full story at Google Alert - BESS Storage